Circulating tumour DNA in multiple myeloma – analysis of the KRAS/NRAS/BRAF mutation in a local cohort

Pathology ◽  
2019 ◽  
Vol 51 ◽  
pp. S127
Author(s):  
Anvita Verma ◽  
Anne-Marie Marivel ◽  
Donna Eng ◽  
Silvia Ling
Keyword(s):  
Multiple Myeloma ◽  
Braf Mutation ◽  
Circulating Tumour Dna

scholarly journals Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer

2018 ◽  
Vol 29 ◽  
pp. viii181 ◽  
Author(s):  
E. Van Cutsem ◽  
K. Lesniewski-Kmak ◽  
M.P. Saunders ◽  
H. Wasan ◽  
G. Argiles ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Braf Mutation ◽  
Digital Pcr ◽  
Droplet Digital Pcr ◽  
Circulating Tumour Dna

DNA-repair gene mutations are prevalent in circulating tumour DNA from advanced multiple myeloma patients

2019 ◽  
Vol 19 (10) ◽  
pp. e79-e80
Author(s):  
Andrew Spencer ◽  
Malarmathy Ramachandran ◽  
Kawa choi ◽  
jay hocking ◽  
Daniela Klarica ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Dna Repair ◽  
Gene Mutations ◽  
Repair Gene ◽  
Dna Repair Gene ◽  
Circulating Tumour Dna

scholarly journals Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates

2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Olena Kis ◽  
Rayan Kaedbey ◽  
Signy Chow ◽  
Arnavaz Danesh ◽  
Mark Dowar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Sequence Analysis ◽  
Dna Sequence ◽  
Dna Sequence Analysis ◽  
Circulating Tumour Dna

scholarly journals Circulating tumour DNA analysis in multiple myeloma

Oncotarget ◽  
2017 ◽  
Vol 8 (53) ◽  
pp. 90610-90611 ◽  
Author(s):  
Sridurga Mithraprabhu ◽  
Andrew Spencer
Keyword(s):  
Multiple Myeloma ◽  
Dna Analysis ◽  
Circulating Tumour Dna

scholarly journals RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation

eJHaem ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 318-322
Author(s):  
Baptiste Le Calvez ◽  
Yannick Le Bris ◽  
Guillaume Herbreteau ◽  
Bastien Jamet ◽  
Céline Bossard ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Braf Mutation ◽  
Acquired Resistance ◽  
Myeloma Patient ◽  
Multiple Myeloma Patient ◽  
Ras Mutation

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients

Leukemia ◽  
2019 ◽  
Vol 33 (8) ◽  
pp. 2022-2033 ◽  
Author(s):  
Sridurga Mithraprabhu ◽  
Rachel Morley ◽  
Tiffany Khong ◽  
Anna Kalff ◽  
Krystal Bergin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Therapeutic Response ◽  
Tumour Burden ◽  
Extracellular Rna ◽  
Circulating Tumour Dna

scholarly journals 1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS

2020 ◽  
Vol 31 ◽  
pp. S757-S758
Author(s):  
C. Robert ◽  
K.T. Flaherty ◽  
H.J. Gogas ◽  
A.M. Arance Fernandez ◽  
M. Mandala ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Braf Mutation ◽  
Mutation Status ◽  
Tumour Biopsy ◽  
Circulating Tumour Dna

scholarly journals DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 917
Author(s):  
Sridurga Mithraprabhu ◽  
Jay Hocking ◽  
Malarmathy Ramachandran ◽  
Kawa Choi ◽  
Daniela Klarica ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Dna Repair ◽  
Gene Mutations ◽  
Amplicon Sequencing ◽  
Kras Mutations ◽  
Repair Gene ◽  
Tp53 Mutations ◽  
Dna Repair Gene ◽  
Ctdna Analysis ◽  
Circulating Tumour Dna

Mutational characterisation utilising plasma (PL)-derived circulating tumour DNA (ctDNA) in multiple myeloma (MM) has been recently described. Mutational analyses of paired bone marrow (BM) MM cell DNA and ctDNA from 76 patients (n = 24, new diagnosis (ND), n = 52, relapsed/refractory (RR)) for (ras/raf signaling pathway) and tumour protein p53 (TP53) mutations using the OnTarget™ Mutation Detection (OMD) platform was performed. The total number and proportions of mutations in each of the compartments (BM-specific, PL-specific or shared) was significantly higher in RR patients compared to ND patients (p = 0.0002 and p < 0.0001, respectively). Patients with > 2 mutations or > 1% fractional abundance (FA) in the PL had significantly shorter overall survival (OS) (p = 0.04 and p = 0.0006, respectively). Patients with PL-specific TP53 mutations had significantly shorter OS compared to patients with no PL-TP53 mutations (p = 0.003), while no differences were observed in patients with (K-ras) KRAS mutations. Targeted deep amplicon sequencing (TAS) of matched PL and BM samples from 36 MM patients for DNA-repair and RAS-RAF pathway genes found that DNA-repair genes were present at significantly higher levels in the PL when compared to RAS-RAF mutations (p = 0.0095). We conclude that ctDNA analysis identifies a higher prevalence of potentially actionable DNA-repair gene mutated subclones than BM analysis.

scholarly journals Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma

2018 ◽  
Vol 19 (7) ◽  
pp. 1858 ◽  
Author(s):  
Sridurga Mithraprabhu ◽  
Shreerang Sirdesai ◽  
Maoshan Chen ◽  
Tiffany Khong ◽  
Andrew Spencer
Keyword(s):  
Multiple Myeloma ◽  
Disease Burden ◽  
Dna Analysis ◽  
Circulating Tumour Dna
Sign in / Sign up

Export Citation Format

Share Document